A chymase inhibitor for prevention of heart failure after myocardial infarction and diabetic renal failure has been tested in clinical phase II studies, and while it was shown to be very safe, no clear efficacy has been demonstrated [84,85]. This evidence concerns the gene CMA1 and heart failure.